Superantigen-SEA gene modified tumor vaccine for hepatocellular carcinoma: An in vitro study

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 1

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

247

HTML

1991

Figures (1-7)

229

Sum=2467

Jan 1, 2004 (publication date) through Jul 16, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Liver Cancer

World J Gastroenterol. Jan 1, 2004; 10(1): 53-57
Published online Jan 1, 2004. doi: 10.3748/wjg.v10.i1.53

Full Size Figure Download Figure

Figure 6 HepG2-SEA increased the number of hepG2 specific CTL in T lymphocyte line. Each bar represents average of spots in triplicate wells.

Citation: Lu SY, Sui YF, Li ZS, Ye J, Dong HL, Qu P, Zhang XM, Wang WY, Li YS. Superantigen-SEA gene modified tumor vaccine for hepatocellular carcinoma: An in vitro study. World J Gastroenterol 2004; 10(1): 53-57
URL: https://www.wjgnet.com/1007-9327/full/v10/i1/53.htm
DOI: https://dx.doi.org/10.3748/wjg.v10.i1.53